Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Filippo de Marinis"'
Autor:
Candida Bonelli, Luca Giovanni Ceresoli, Marina Chiara Garassino, Filippo de Marinis, Francesco Grossi, Paolo Andrea Zucali, Nicola Normanno, Alessia Ciarrocchi, Hector Soto Parra, Maria Pagano, Federico Cappuzzo, Paolo Pedrazzoli, Marcello Tiseo, Federica Torricelli, F. Zanelli, Carmine Pinto, R. Gnoni, Federica Grosso, Giulia Pasello
Publikováno v:
Cancers
Cancers, Vol 12, Iss 2948, p 2948 (2020)
Volume 12
Issue 10
Cancers, Vol 12, Iss 2948, p 2948 (2020)
Volume 12
Issue 10
Purpose: Malignant pleural mesothelioma (MPM) is an aggressive cancer. Data are not available in prospective trials on correlations between genetic alterations and outcomes of therapies. In this study, we assessed the genetic profile of MPM patients
Autor:
Belen San Antonio, Giorgio V. Scagliotti, Carla Visseren-Grul, Ana B Oton, Jingyi Liu, Jian Chen, Filippo de Marinis, Jean-Louis Pujol, Corey J. Langer, Cesare Gridelli, Antoinette J. Wozniak, Luis Paz-Ares
Publikováno v:
Clinical Lung Cancer
Clinical Lung Cancer, Elsevier, 2017, 18 (5), pp.489--496. ⟨10.1016/j.cllc.2017.04.003⟩
Clinical Lung Cancer, Elsevier, 2017, 18 (5), pp.489--496. ⟨10.1016/j.cllc.2017.04.003⟩
Background In a phase III study, maintenance pemetrexed showed superior survival over placebo (PARAMOUNT) for patients with advanced non-squamous non-small cell lung cancer (NSCLC) who completed 4 cycles of pemetrexed plus cisplatin (PC) induction th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba228ff49b6e7c3e6f85d91043f1a1ce
http://hdl.handle.net/2318/1680276
http://hdl.handle.net/2318/1680276
Autor:
Massimo Di Maio, Federico Cappuzzo, Francesco Perrone, Luigi De Petris, Filippo de Marinis, Fortunato Ciardiello, Robert Pirker, Rolf A. Stahel, Panagiotis Fidias, Luis Paz-Ares, Chandra P. Belani, Andrea Ardizzoni, Cesare Gridelli
Publikováno v:
Lung Cancer. 76:269-279
Several randomized trials have recently investigated the role of maintenance treatment for patients with advanced non-small-cell lung cancer (NSCLC) with responding or stable disease after completion of first-line chemotherapy. Maintenance strategy h
Autor:
Oscar Alabiso, Vincenzo Adamo, Santi Barbera, Filippo de Marinis, R. Morena, Andrea Ardizzoni, Paolo Maione, Cesare Gridelli, Paola Venturino, Sandro Barni, Vito Lorusso, Vittorio Gebbia, E. Piazza, Calogero Buscarino, Nicoletta Zilembo, Alberto Caprioli, Maurizio Marangolo, Lucio Crinò, Riccardo Pela, Gianfranco Filippelli
Publikováno v:
Lung Cancer. 74:462-468
Lung cancer is the most common cancer in the world today, in terms of both incidence and mortality. Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancers, and the majority of people diagnosed with NSCLC have locally advanced o
Autor:
Serena Ricciardi, Filippo de Marinis
Publikováno v:
European Journal of Cancer. 47:S258-S271
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related death in both men and women in most of the Western world, with an estimated 900,000 deaths per year worldwide [1]. Most patients (approximately 80%), present with locally
Autor:
Frances A. Shepherd, Filippo de Marinis, Cesare Gridelli, Andrea Ardizzoni, Massimo Di Maio, Rafael Rosell, Jean-Yves Douillard, Francesco Perrone, Christian Manegold, Robert Pirker, Luigi De Petris, Nasser H. Hanna
Publikováno v:
Lung Cancer. 68:319-331
Platinum-based chemotherapy is the standard first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC). However, randomized trials have recently demonstrated the efficacy of several new drugs (pemetrexed, bevacizumab, cetuxima
Publikováno v:
Lung Cancer. 67:339-342
Purpose and methods To evaluate how the new strategic approaches impact on clinical practice for the treatment of advanced non-small cell lung cancer (NSCLC) in Italy, an Italian survey was launched through the Italian Association of Thoracic Oncolog
Publikováno v:
Lung Cancer. 66:141-149
Pemetrexed, a new cytotoxic agent, is a potent inhibitor of thymidylate synthase and other folate-dependent enzymes. Firstly, pemetrexed was approved in combination with cisplatin for the treatment of malignant pleural mesothelioma. Successively, it
Autor:
Filippo de Marinis, Kurt Banz, Christos Chouaid, Matthias Brunner, Stefan Walzer, Alain Vergnenegre, Francesco Grossi, Helge Bischoff, Javier de Castro Carpeño
Publikováno v:
Lung Cancer
Lung Cancer, 2011, 74 (3), pp.529-534. ⟨10.1016/j.lungcan.2011.04.010⟩
Lung Cancer, Elsevier, 2011, 74 (3), pp.529-534. ⟨10.1016/j.lungcan.2011.04.010⟩
Lung Cancer, 2011, 74 (3), pp.529-534. ⟨10.1016/j.lungcan.2011.04.010⟩
Lung Cancer, Elsevier, 2011, 74 (3), pp.529-534. ⟨10.1016/j.lungcan.2011.04.010⟩
International audience; Objective of this indirect economic comparison was to estimate and compare management costs of grade 3/4 adverse events (AEs) reported for first-line erlotinib or pemetrexed maintenance therapy in patients with advanced non-sm
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 69
Introduction The new targeted agent bevacizumab in combination with cisplatin and gemcitabine (BCG), and a third-generation chemotherapy pemetrexed in combination with cisplatin (PC), are approved as first-line treatment for patients with advanced no